Drug intelligence / Profile preview

metiapine

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Metiapine is a small molecule classified as a dibenzothiazepine derivative. It has been investigated for its potent antipsychotic characteristics, particularly in the treatment of schizophrenia. Its mechanism of action involves blocking GABA(A) receptors, a property it shares with other antipsychotic and antidepressant drugs like clozapine. Clinical trials in the 1970s compared metiapine to chlorpromazine for acute and chronic schizophrenia, with a 2017 review concluding that further research comparing the two drugs was unlikely due to a lack of clinical relevance.

Targets

GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)

Beyond the preview

Go deeper on metiapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metiapine.

Explore the full profile